Materials and methods for modulating T cell mediated immunity
Anti-TRGV9 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
1 . An antibody that binds to T Cell Receptor Gamma Variable 9 (TRGV9), wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody comprises: (i) a VH comprising a VH CDR1 having the amino acid sequence of SEQ ID NO: 107, a VH CDR2 having the amino acid sequence of SEQ ID NO: 108, and a VH CDR3 having the amino acid sequence of SEQ ID NO: 109; and (ii) a VL comprising a VL CDR1 having the amino acid sequence of SEQ ID NO: 110, a VL CDR2 having the amino acid sequence of SEQ ID NO: 111, and a VL CDR3 having the amino acid sequence of SEQ ID NO:112.
2 . The antibody of claim 1 , wherein the antibody comprises a VH having the amino acid sequence of SEQ ID NO:113.
3 . The antibody of claim 1 , wherein the antibody comprises a VL having the amino acid sequence of SEQ ID NO:114.
4 . A vector comprising a nucleic acid encoding the antibody of claim 1 .
5 . A host cell comprising the vector of claim 4 .
6 . A pharmaceutical composition comprising the antibody of claim 1 , and a pharmaceutically acceptable carrier.